Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy

Lee, Victor; Chan, Wendy; Lee, Elaine; Choy, T. T. C.; Ho, P.; Leung, Dennis K.C.; Lam, Ka-On; Kwong, Dora L.W.; Leung, TW; Khong, Pek‐Lan

doi:10.1097/coc.0000000000000070

Cited by 12 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three size-related prognostic factors were found across 38 inclusions (Table 3): Tumor diameter [16,32,34,38,45,48-52,57,58 ,60,68,69,78,83], Tumor volume [16,18,66,67,71,73,80,81], and Gross Tumor Volume (GTV) [11,13,15,18,21,35,41,47,54,64,65,70,73,74,76,77,80]. Tumor volume and GTV were considered unique prognostic factors, as GTV encompasses both the volume of the primary tumor and involved lymph nodes [11,13,15,18,41,64,65], where tumor volume includes only primary tumor volume [13,16,66,67,71].…”

Section: Resultsmentioning

confidence: 99%

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Laar

Amsterdam

Lindert

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

Introduction: Prognosis prediction is central in treatment decision making and quality of life for nonsmall cell lung cancer (NSCLC) patients. However, conventional computed tomography (CT) related prognostic factors may not apply to the challenging stage III NSCLC group. The aim of this systematic review was therefore to identify and evaluate CT-related prognostic factors for overall survival (OS) of stage III NSCLC. Methods: The Medline, Embase, and Cochrane electronic databases were searched. After study selection, risk of bias was estimated for the included studies. Meta-analysis of univariate results was performed when sufficient data were available. Results: 1595 of the 11,996 retrieved records were selected for full text review, leading to inclusion of 65 studies that reported data of 144,513 stage III NSCLC patients andcompromising 26 unique CT-related prognostic factors. Relevance and validity varied substantially, few studies had low relevance and validity. Only four studies evaluated the added value of new prognostic factors compared with recognized clinical factors. Included studies suggested gross tumor volume (meta-analysis: HR = 1.22, 95%CI: 1.05-1.42), tumor diameter, nodal volume, and pleural effusion, are prognostic in patients treated with chemoradiation. Clinical T-stage and location (right/left) were likely not prognostic within stage III NSCLC. Inconclusive are several radiomic features, tumor volume, atelectasis, location (pulmonary lobes, central/peripheral), interstitial lung abnormalities, great vessel invasion, pit-fall sign, and cavitation. Conclusions: Tumor-size and nodal size-related factors are prognostic for OS in stage III NSCLC. Future studies should carefully report study characteristics and contrast factors with guideline recognized factors to improve evidence evaluation and validation.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Laar

Amsterdam

Lindert

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…The other 16 studies used multiple segmentation methods and the results of the studies were summarized in Table 3. Among the 16 studies, 11 studies evaluated the predictive value of MTV [23,[52][53][54][55][56][57][58][59][60][61]. Seven studies showed comparable predictive value between the different segmentation methods.…”

Section: Comparison Of the Fdg Pet Tumor Segmentation Methodsmentioning

confidence: 99%

Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Bradshaw

Solaiyappan

et al. 2017

Nucl Med Mol Imaging

202

190

View full text Add to dashboard Cite

Numerous methods to segment tumors using F-fluorodeoxyglucose positron emission tomography (FDG PET) have been introduced. Metabolic tumor volume (MTV) refers to the metabolically active volume of the tumor segmented using FDG PET, and has been shown to be useful in predicting patient outcome and in assessing treatment response. Also, tumor segmentation using FDG PET has useful applications in radiotherapy treatment planning. Despite extensive research on MTV showing promising results, MTV is not used in standard clinical practice yet, mainly because there is no consensus on the optimal method to segment tumors in FDG PET images. In this review, we discuss currently available methods to measure MTV using FDG PET, and assess the advantages and disadvantages of the methods.

show abstract

“…From the view of tumor cell metabolic capacity, high standard uptake value (SUV max) of the tumor area may be related to poor survival among stage I to III disease. 6 , 7 Among patients who received anatomic resection and were identified as pathologic stage IIIA, pathologic tumor classification and mediastinal lymph node involvement have been identified as independent prognostic factors for disease-free survival. 8 In addition, patients without lymph node involvement or with lower metastatic lymph node ratio have been correlated to better survival.…”

Section: Introductionmentioning

confidence: 99%

Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection

et al. 2015

Medicine

View full text Add to dashboard Cite

The current TNM staging system did not provide disease relapse information. The aim of study was try to establish a predictive survival model for disease and overall survival in nonsmall cell lung cancer patients who presented as resectable disease and to develop a reference for follow-up imaging tool selection.From January 2005 to December 2011, 442 patients who initially presented as resectable disease (stages I–IIIa) and received anatomic resection and mediastinal lymph node dissection were included in the study.Medical charts were thoroughly reviewed and clinico-pathologic factors were collected and analyzed.Visceral pleural invasion, tumor size >5 cm, and postoperative adjuvant therapy were identified as risk factors for poorer disease-free survival. The 5-year disease-free survival from score 0 to 3 was 68.7%, 46.6%, 31.9%, and 26.1%, respectively. The disease relapse percentage for scores 0 to 3 were 26.49%, 50.61%, 65.05%, and 73.81%, respectively. For analysis of overall survival, age >60 years, tumor size >3 cm, and total metastatic lymph node ratio >0.05 were correlated to worse overall survival. Because greater age may be correlated with poor general condition, we re-scored risk factors that correlated to disease severity that ranging from 0 to 2. The 5-year overall survival range from score 0 to 2 was 56.3%, 43.1%, and 13.1%, respectively.Poor prognostic factors correlated to disease-free survival were tumor size >5 cm, visceral pleural invasion, and patients needing to receive postoperative adjuvant therapy. Disease-free survival of resectable nonsmall cell lung cancer patients and disease relapse can be stratified by these 3 factors. Chest tomography may be recommended for patients with 1 or more poor disease-free survival risk factors.

show abstract

Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy

Abstract: SUVmax nodes <8 was the only prognostic factor of PFS, DMFS, and OS in our study. PET-CT scan at the time of diagnosis is useful in stratifying patients into favorable and unfavorable groups in stage III NSCLC treated with definitive concurrent chemoradiotherapy.

Cited by 12 publications

References 31 publications

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis

Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection

Contact Info

Product

Resources

About